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Inflammatory rheumatic diseases (IRD) are associated with accelerated coronary artery
disease (CAD), which may result from both systemic and vascular wall inflammation.
There are indications that complement may be involved in the pathogenesis of CAD in
Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). This study aimed to
evaluate the associations between circulating complement and complement activation
products with mononuclear cell infiltrates (MCI, surrogate marker of vascular inflamma-
tion) in the aortic media and adventitia in IRDCAD and non-IRDCAD patients undergoing cor-
onary artery bypass grafting (CABG). Furthermore, we compared complement activation
product deposition patterns in rare aorta adventitial and medial biopsies from SLE, RA and
non-IRD patients.
Methods
We examined plasma C3 (p-C3) and terminal complement complexes (p-TCC) in 28 IRDCAD
(SLE = 3; RA = 25), 52 non-IRDCAD patients, and 32 IRDNo CAD (RA = 32) from the Feiring
Heart Biopsy Study. Aortic biopsies taken from the CAD only patients during CABG were
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previously evaluated for adventitial MCIs. The rare aortic biopsies from 3 SLE, 3 RA and 3
non-IRDCAD were assessed for the presence of C3 and C3d using immunohistochemistry.
Results
IRDCAD patients had higher p-TCC than non-IRDCAD or IRDNo CAD patients (p<0.0001), but
a similar p-C3 level (p = 0.42). Circulating C3 was associated with IRD duration (ρ, p-value:
0.46, 0.03). In multiple logistic regression analysis, IRD remained significantly related to the
presence and size of MCI (p<0.05). C3 was present in all tissue samples. C3d was detected
in the media of all patients and only in the adventitia of IRD patients (diffuse in all SLE and
focal in one RA).
Conclusion
The independent association of IRD status with MCI and the observed C3d deposition sup-
ports the unique relationship between rheumatic disease, and, in particular, SLE with the
complement system. Exaggerated systemic and vascular complement activation may accel-
erate CVD, serve as a CVD biomarker, and represent a target for new therapies.
Introduction
Inflammatory rheumatic diseases (IRD), such as systemic lupus erythematosus (SLE) or rheu-
matoid arthritis (RA), are associated with increased cardiovascular (CV) risk, which is not
fully explained by traditional CV factors. The progression of CVD is in part related to an
inflammatory response mediated by immune processes.
It is notable that not only systemic inflammation, but also inflammation within the vessel
wall, including the deep vascular and perivascular layers, may play an essential role in ather-
oma formation and destabilization. Previous results from the Feiring Heart Biopsy Study
(FHBS) demonstrated that mononuclear cell infiltrates (MCI) occur in the aortic media and
adventitia of patients with coronary artery disease (CAD), with a higher occurrence and a
greater extent in patients with IRD than non-IRD patients.[1, 2] It is possible that the sub-inti-
mal inflammation may play a role in the pathogenesis of CVD, and premature CVD in IRD.
Circulating complement protein C3 (plasma C3, p-C3), a critical protein in the classical,
mannose and alternative pathways, is a biomarker routinely used to monitor disease activity in
SLE. Furthermore, C3 is known to be associated with subclinical measures of CVD such as vas-
cular stiffness.[3–6] In animal models, vascular complement deposition associated with vascu-
lar stiffness is likely due to complement binding directly to the elastin and collagen fibers
within the vascular wall.[7, 8] The potentially pathogenic role of complement in the develop-
ment of CVD is highlighted in a C4-deficient patient with well-preserved elastic arteries
despite aging and a medical condition associated with vascular stiffness.[9]
Complement activation products and, in particular, cell bound complement activation
products (CB-CAPs) on circulating erythrocytes, platelets and lymphocytes, have been shown
to be highly specific for SLE as diagnostic, monitoring and prognostic biomarkers.[10–12]
Additional circulating biomarkers indicative of complement cascade activation and inflamma-
tion include the culminating formation of terminal complement complexes (p-TCC)[13] and
circulating molecules such as pentraxin 3 (PTX3), which mediates the effects of complement
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activation within the alternative pathway and has been implicated in vascular inflammation.
[13–15]
Exaggerated complement activation as a result of chronic inflammatory rheumatic disease
(IRD) along with advanced CVD may increase both systemic and local inflammation causing
vascular tissue damage, which may be involved in CVD pathogenesis. Therefore, in this study,
we assessed expression of the parent complement factor C3 and its activation product C3d,
along with the occurrence and extent of MCI (a marker of vascular inflammation), within the
sub-intimal layers of the aortic wall in CAD patients with IRD (RA or SLE) or without IRD.
Furthermore, we compared circulating levels of C3 and TCC within these patient groups, and




Among patients undergoing coronary artery bypass grafting (CABG) included in FHBS,
described elsewhere[1], we examined all RA patients fulfilling ACR 1987 criteria (RA, n = 25)
and SLE patients fulfilling ARA 1982 criteria (SLE, n = 3) representing IRDCAD (n = 28), and
52 non-IRDCAD patients in whom aortic biopsies and/or blood samples were available. The
exclusion criteria for both groups were age<18 years, psoriasis, and clinically significant
infection or malignancy. The Regional Committee for Medical and Health Research Ethics
approved the study protocol and all of the patients gave written informed consent.[1] Further-
more, we examined 32 RA patients fulfilling ACR criteria without CAD (IRDNo CAD). The
inclusion criteria for this IRDNo CAD group were age> 18 years, RA according to 1987 ACR
criteria, absence of CAD (based on medical history and clinical and electrocardiographic find-
ings) and any clinically significant infection or malignancy. The IRDCAD and non-IRDCAD
groups were matched for age and sex. It was not feasible to identify and include older IRD
patients without subclinical or clinical CAD manifestations. The IRDNo CAD group was
matched for sex to the RA subgroup within IRDCAD.
Data collection, aortic biopsies and laboratory analyses
The patients were examined by preoperative blood tests, interviews, physical examinations,
and self-reported questionnaires, and by biopsies taken during CABG.[1]
Aortic biopsy. The details of the aortic biopsy have been previously described.[1] Briefly,
aortic specimens were obtained from tissue routinely removed during CABG surgery in con-
nection to establishment of aorto-coronary anastomoses. The aortic biopsies were obtained in
a two-step process: at first, a part of the adventitia (5–10 mm) was removed from the ventral
part of the ascending aorta. After that, an opening (4.8 mm in diameter) through the rest of
the vessel wall in the same area was made using a punch device. The punch specimens con-
tained a cross-section of intima, media and at times, a thin layer of adventitia. For surgical
safety (to avoid thromboembolism), the anastomoses were preferably made at sites with less
pronounced gross signs of atherosclerosis. Thus, the specimens were taken from relatively
healthy areas of the ascendant aorta. Both types of specimens (the adventitia and the punch
specimen) were fixed in formalin and embedded in paraffin [1].
Assessment of pathologic features. Previously, 3-μm thick sections, stained by hematox-
ylin-eosin (H&E), were examined in random order by light microscopy, by 2 independent
pathologists blinded to the clinical data, for the presence and localization of atherosclerotic
lesions and MCIs.[1] At the level where the biopsies are taken, the aortic adventitia is covered
by the aortic part of the epicardium. MCIs adjacent to the mesothelium were classified as
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submesothelial (epicardial), unless there was diffuse spreading into the inner adventitia. The
size of the largest MCI in a single section was classified according to the number of mononu-
clear cells: either none, <50 or 50 cells. Data on aortic MCI in the whole FHBS population
(including several rheumatic diagnoses than the current sub-study) have been published previ-
ously [1].
Immunohistochemistry (IHC). Serial sections of RA (n = 3), SLE (n = 3) and non-IRD
(n = 3) were sent for an explorative IHC evaluation to the Lupus Center of Excellence in Pitts-
burgh. The rarity of the IRD patient biopsies, and, in particular the SLE biopsies, is a limitation
within this IHC analysis; however, Aubry, et al, also performed a preliminary IHC analysis on
limited RA coronary artery biopsies.[16]
Briefly, paraffin embedded samples were sectioned at 5μm. Standard IHC techniques were
used to evaluate anti-human monoclonal C3 (Santa Cruz Biotechnology, Inc, Dallas, TX) and
anti-human monoclonal C3d (Quidel Corporation, San Diego, CA) deposition within the tis-
sue samples. Briefly, the tissue slides were deparaffinized using serial ethanol dilutions and
rehydrated. Antigen retrieval was achieved through subsequent washes in 3.0% hydrogen per-
oxide, Tris-Buffered Saline and Tween 20 (TBST), microwave heated citrate, and then incuba-
tion in proteinase K with a rinse in TBST. Samples were then incubated in 3.0%BSA overnight
at 4˚C. HRP and AEC (DAKO kit) with a hematoxylin counterstain were completed the fol-
lowing day.
Blood tests. We collected fasting blood samples, and performed hematological, serological
and plasma analyses as described previously.[1, 17] Except for routine tests, the samples were
analyzed in batches (after storage in -80˚C) in random order, by assessors blinded for the clini-
cal data. Plasma was carefully obtained by rapid centrifugation and immediately stored at
-80˚C.[18] Circulating C3 was measured by nephelometry (Siemens BN ProSpec, Germany)
and circulating TCC and pentraxin 3 levels were measured by commercially available ELISAs
as previously described.[18, 19]
Statistical analysis. The chi-square test and Fisher’s exact test (for categorical variables),
and the Kruskal-Wallis Test (for continuous skewed variables) were used to identify differences
between the three groups (IRDNo CAD (RA only, Group 1), Non-IRDCAD (Group 2), and
IRDCAD (SLE and RA, Group 3)). Post hoc pairwise comparisons were completed using either
false discovery rate (categorical variables) or rank based nonparametric ANOVA (continuous
variables) with adjusted p-values. Combining the two rheumatic diseases into one CAD group
is not without precedence due to the rarity of SLE patients undergoing CABG.[20] Non-
parametric Spearman correlations were performed between circulating complement factors
(C3 and TCC) and known CVD risk factors and known circulating inflammatory markers only
within the Non-IRD CAD and IRD (SLE and RA) CAD groups. No tissue samples could be
obtained to evaluate the presence of MCIs in the IRD (RA only) no CAD group, therefore only
the Non-IRD CAD and IRD CAD groups were evaluated using regression analyses. Simple
logistic regression analysis was used to assess the relationships between the presence and size of
adventitial MCIs (MCI50 cells: yes/no) and a set of covariates, which included the comple-
ment proteins of interest and known CVD risk factors and circulating inflammatory markers.
In multiple logistic regression analysis, we created 3 separate models adjusting for 1) age and
gender, 2) age, gender, and traditional CVD risk factors (a. history of thrombosis (which
included any myocardial infarction (MI), stroke, acute coronary syndrome (ACS), deep vein
thrombosis (DVT), or pulmonary embolism (PE)), b.) hypertension, c.) current smoker, d.)
family history of CVD, e.) BMI), 3) age, gender, and circulating inflammatory markers (a.) C3,
b.) TCC, c.) PTX3, d.) CRP). All estimates were performed with SAS for Windows, version 9.4
(SAS, Cary, NC) and R-Project, package fifer for post hoc pairwise comparison using false dis-
covery rate. The level of significance was set at 0.05, and all statistical tests were 2-sided.
Circulating and deposited complement in rheumatic aorta biopsies
PLOS ONE | https://doi.org/10.1371/journal.pone.0174577 March 31, 2017 4 / 12
Results
Demographics and clinical characteristics
The characteristics of the patients are shown in Table 1. The median (25th-75th%) age of
IRDNo CAD was 57(52–66), Non-IRDCAD was 70.0 (64–78), and IRDCAD was 70.5 (62–76)years
old. Twenty-four IRDNo CAD (75%), 18 non-IRDCAD (35%), and 13 IRDCAD (46%: SLE, n = 2
and RA, n = 11) patientswere female (Table 1). All participants were from Norway, and all
were Caucasian. (S1 Table)
As expected, the IRDCAD patients had higher circulating levels of systemic inflammatory
biomarkers (ESR, CRP and PTX3) when compared to the IRDNo CAD and Non-IRDCAD. Cir-
culating TCC was significantly higher in IRDCAD (SLE: 1.4(0.85–1.75) and RA: 1.3(0.9–1.55)
CAU/ml) when compared to IRDNo CAD or non-IRDCAD; however, there was no difference
between IRDNo CAD and non-IRDCAD. Furthermore, IRDCAD also had a higher occurrence of
previous myocardial infarctions (MIs) when compared to the non-IRDCAD patients. (Table 1)
Relationship between circulating C3 and TCC levels with clinical and
laboratory variables
In non-IRDCAD patients, circulating C3 levels were positively correlated to BMI (ρ, p-value:
0.51, 0.0001) and CRP (0.39, 0.004), and circulating TCC levels were positively correlated with
CRP (0.35, 0.011). In the IRDCAD group, circulating C3 levels were significantly associated
only with IRD disease duration (0.46, 0.03).
Relationship between MCI and clinical and laboratory variables
In simple logistic regression analysis, the presence of IRD was significantly associated with the
presence of MCI (OR[95% CI]: 4.30[1.5–12]), and even more strongly with the presence of
MCI 50 (5.06[1.5–17]), in the aortic adventitia. The presence of MCI was also positively
related to CRP, and the occurrence of 50 MCI to hypertensive status and current smoking.
(Table 2)
In multiple logistic regression analysis, the association between IRD and the presence of
adventitial MCIs and the presence of MCI 50 was significant in Model 1and 2. In model 3,
adjusting for circulating inflammatory markers slightly attenuated the association between
IRD and MCI (p = 0.055), but the association to MCI 50 remained statistically significant
(p = 0.03).(Table 3)
Immunohistochemistry: C3 and C3d detection
Parent complement protein C3 was detected in a diffuse pattern within the aortic media and
adventitia of all samples, regardless of IRD status.(not shown)
More importantly, the C3 activation product, C3d, was detected in a diffuse pattern
throughout the aortic media of all tissue specimens regardless of IRD (Fig 1A–1C). However,
C3d deposition was detected exclusively in all SLE adventitial samples (Fig 1G and SLE-1-3).
One SLE adventitial sample had an overall diffuse pattern of C3d deposition (Fig 1G, SLE-1)
while the other two SLE adventitia had a more localized pattern (Fig 1: SLE-2 and -3). Limited
focal deposition surrounding the adventitial vasculature occurred also in 1 RA patient (Fig
1H). No C3d was detected in the non-IRDCAD adventitial samples (Fig 1I).
SLE adventitia only—different C3d deposition patterns: SLE-1) Higher magnification
(40x) of the diffuse C3d pattern found in the SLE biopsy (Fig 1G); SLE-2 and -3) Other 2 SLE
adventitial biopsies with a localized C3d presence, (10x). C3d = red-brown for all images.
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Discussion
To our knowledge, this is the first study to evaluate complement protein deposition within the
vessels of SLE, RA, and non-IRD patients with CAD. The findings support the unique relation
between complement and IRD, in particular SLE. From these findings, two important ques-
tions arise, which include the source and the targets of the complement and the complement
activation products.
Traditionally, the source of complement for deposition within various tissues types has
been associated with systemic circulation. Another possible source is the perivascular adipose
tissue (PVAT) surrounding the vascular wall, which is not anatomically separated from the








Overall p-value Post Hoc Pairwise Comparisons†
n = 32 n = 52 n = 28 (Group 1 vs 2 vs 3)
Gender, Female 24/32(75%) 18/52(35%) 13/28(46%) 0.002 1 v 2; 1 v 3
Age, years 57(52–66) 70(64–78) 70.5(62–76) 0.0001 1 v 2; 1 v 3
BMI, kg/m2 24(22–27) 25(24–28) 25(21–28) 0.52 --
Smoke ever 0/31(0%) 25/52(48%) 11/28(39%) <0.0001 1 v 2; 1 v 3
Smoke now 18/31(58%) 7/52(13%) 6/28(21%) <0.0001 1 v 2
CRP, mg/L 3(2–8) 2.3(1.1–5.1) 9.9(2.5–20) 0.0016 2 v 3
Triglycerides 1.15(0.79–1.4) 1.45(1–1.8) 1.75(1–2) 0.026 1 v 3
Cholesterol 5.45(4.6–6) 4.95(4.3–5.4) 4.8(4.3–5.6) 0.15 --
LDL 3.4(2.4–3.9) 2.9(2.6–3.5) 3(2.7–3.65) 0.92 --
PTX3, ng/ml N/A 1.34(0.78–2.1) 1.83(1.2–2.9) 0.02 --
ESR, mm/hour 13(7–21) 13(6–23) 24(16–48) 0.005 1 v 3; 2 v 3
MCV, fL/RBC 89.5(86–94) 23(18–32) 18(15–25) 0.0001 1 v 2; 1 v 3
TCC, CAU/ml 0.7(0.4–0.8) 0.7(0.6–0.8) 1.3(0.9–1.6) <0.0001 1 v 3; 2 v 3
Circulating C3, g/L 1.11(0.98–1.2) 1.15(1.0–1.4) 1.13(1.1–1.3) 0.42 --
CVD History
Hypertension 7/28(25%) 30/52(58%) 18/28(64%) 0.005 1 v 2; 1 v 3
Family History CVD 9/27(33%) 32/52(81%) 19/28(68%) <0.0001 1 v 2; 1 v 3
Myocardial Infarction 0/32(0%) 23/52(44%) 20/28(71%) <0.0001 1 v 2; 1 v 3
Acute Coronary Syndrome 0/32(0%) 12/42(23%) 9/28(32%) 0.001 1 v 2; 1 v 3
Stroke 0/32(0%) 3/50(6%) 3/28(11%) 0.10 --
DVT 0/32(0%) 3/42(7.1%) 0/27(0%) 0.18 --
CAD duration, months N/A 41(12–122) 24(6–113) 0.34 --
Localized Aortic Inflammation
MCI* N/A 10/50(20%) 13/25(52%) 0.005 --
MCI50** N/A 5/50(10%) 9/25(36%) 0.01 --
Median (25th-75th%) or n/total (%) Body mass index (BMI), C-reactive protein (CRP), Low Density Lipoprotein (LDL), Pentraxin3 (PTX3), Erythrocyte
Sedimentation Rate (ESR), Mean Corpuscular Volume (MCV), Terminal Complement Complex (TCC, reference range (ref): <0.7 CAU/ml)[18],
Complement C3 (ref, assay specific: 0.70–2.00 g/L), Deep Vein Thrombosis (DVT), Mononuclear cell infiltrates (MCI)
* presence within adventitial aorta,
**extent (50) within adventitial aorta.
Post hoc pairwise comparisons adjusted p-values: False Discovery Rate (FDR) (for categorical variables) and rank based nonparametric ANOVA (for
continuous variables).
†Only the groups with statistically significant post hoc comparisons are shown.
https://doi.org/10.1371/journal.pone.0174577.t001
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adventitia. As mentioned above, complement activation in the adventitia occurred only in a
subset of IRDCAD patients. The adventitial samples have an extensive number of adipocytes
that are not found in the media samples. Adipose tissue is known to produce complement pro-
teins [21], and visceral adipose tissue is strongly associated with CVD. IRD patients are predis-
posed to greater volumes of visceral adipose when compared to the general population.[22, 23]
We have previously found increased volumes of localized PVAT surrounding the aorta in
women with SLE when compared to their age- and race-matched healthy controls despite no
differences in BMI.[24] These small visceral vascular and perivascular depots may have a local-
ized influence on vascular health and contribute to the progression of CVD from the ‘outside-
in’.[25]
Liu et al has established that various circulating cell types are targets of complement activa-
tion products (cell bound-CAPs), which are highly specific to SLE and associated with all-cause
mortality and stroke.[10–12] Additionally, in mouse models of CVD, we have found comple-
ment proteins (C3 and C4) targeting the collagen and elastin within the aortic vascular wall
regardless of luminal athero-lesion development, and associated with increased vascular stiff-
ness.[7,8] The role of complement contributing to vascular stiffness and CVD is highlighted by
a remarkable clinical example of a 51 year old, kidney transplant candidate with hereditary
complement protein C4 deficiency. The patient was found to have a central vascular stiffness
similar to that of an adolescent and a carotid wall thickness better than normal for the patient’s
age group.[9] Complement activation products may target both circulating immune cells and
structural proteins of the vascular wall. Each of these mechanisms may be important biomark-
ers of CV events [12] and in CVD pathogenesis [6–9].
Our present findings show that parent complement deposition exists within the vascular
wall in patients with CAD regardless of IRD status. However, those with SLE or RA, exhibit
inflammation both within the vascular wall, marked by increased MCIs and complement
activation products, and systemically, through higher circulating levels of inflammatory
Table 2. Simple logistic regression analysis on presence and extent of adventitial MCI (50) with clinical and laboratory parameters.
Presence of MCI p-value Extent of MCI > = 50 p-value
(OR[95%CI]) (OR[95%CI])
Presence of IRD 4.30[1.5–12] 0.006 5.06[1.5–17] 0.01
Female 0.79[0.28–2.2] 0.64 1.24[0.38–4.0] 0.72
Age 0.99[0.94–1.0] 0.54 0.99[0.94–1.0] 0.73
BMI 0.87[0.75–1.0] 0.07 0.91[0.77–1.1] 0.28
C3 1.90[0.28–13] 0.52 8.94[0.88–91] 0.064
CRP 1.11[1.0–1.2] 0.008 1.05[0.98–1.1] 0.13
Cholesterol 1.06[0.64–1.7] 0.83 1.12[0.64–2.0] 0.7
LDL 1.07[0.60–1.9] 0.82 1.11[0.59–2.1] 0.74
Triglycerides 1.10[0.53–2.3] 0.81 1.32[0.60–2.9] 0.49
Pentraxin 3 0.60[0.31–1.1] 0.12 0.927[0.46–1.9] 0.83
MCV 0.98[0.95–1.0] 0.23 0.985[0.95–1.0] 0.40
TCC 2.46[0.78–7.8] 0.13 2.42[0.66–8.9] 0.18
History of thrombosis* 1.11[0.38–3.2] 0.85 1.22[0.34–4.4] 0.76
Hypertension 2.62[0.89–7.7] 0.08 5.44[1.1–26] 0.04
Smoke current 1.79[0.50–6.4] 0.37 4.29[1.1–16] 0.034
Body mass index (BMI), C-reactive protein (CRP), Low Density Lipoprotein (LDL), Pentraxin3 (PTX3), Mean Corpuscular Volume (MCV), Terminal
Complement Complex (TCC).
*History of Thrombosis: myocardial infarction (MI), stroke, acute coronary syndrome (ACS), deep vein thrombosis (DVT), or pulmonary embolism
https://doi.org/10.1371/journal.pone.0174577.t002
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biomarkers. The younger RA group with no subclinical or clinical history of CAD had circulat-
ing TCC levels similar to that of nonIRD CAD patients approximately 15 years older and in
need of CABG. These high circulating TCC levels support existing literature citing there is
systemic, circulating inflammation occurring in IRD patients that may be contributing to
CAD progression. The increased circulating TCC in the IRDCAD (SLE and RA) group reflects
increased basic complement activation [14], and may be mediated by increased levels of PTX3,
which is known to regulate complement activation.[15]
Notably, PTX3 is an acute phase reactant and higher PTX3 levels were protective against
the presence of adventitial MCI. A potential protective role of PTX3 in CVD has been demon-
strated in previous studies. The protective role of PTX3 in CVD is supported by an animal
model of acute MI, which showed increased myocardial damage along with increased C3
deposition in PTX3 deficient mice.[26] PTX3 is known to modulate activation of the alterna-
tive pathway through Factor H and down-regulate exaggerated inflammation by suppressing
leucocyte extravasation through P-selectin.[27–29] Additionally, circulating C3 was positively
correlated with IRD duration in our study thus underscoring the potential role of long-term
IRD-associated inflammation on cardiovascular health.
Furthermore, despite no differences in age and the advanced CAD necessitating CABG for
both groups, the SLE and RA CAD patients suffered a higher number of MIs compared to the
non-IRDCAD group, which highlights the accelerated CVD progression within IRD. Taken
together, our results support the notion that controlling complement activation may be
Table 3. Multiple logistic regression analysis on presence and extent of adventitial MCI (50) with clinical and laboratory parameters.
Adjusting for gender and age
Model I Presence of MCI p-value Presence of MCI50 p-value
Presence of SLE and RA 4.68 [1.6–14] 0.005 5.01 [1.4–17] 0.01
+ Female 0.633[0.20–2.0] 0.44 1.05[0.28–3.9] 0.94
+ Age 0.99[0.94–1.0] 0.76 0.99[0.93–1.1] 0.79
Adjusting for traditional CVD risk factors
Model II Presence of MCI p-value Presence of MCI50 p-value
Presence of SLE and RA 5.66[1.5–21] 0.01 6.13[1.3–30] 0.03
+Female 0.313[0.07–1.3] 0.11 0.822[0.16–4.3] 0.82
+Age 0.971[0.91–1.0] 0.35 0.990[0.92–1.1] 0.80
+History of Thrombosis* 0.654[0.17–2.5] 0.53 0.605[0.12–3.1] 0.55
+Hypertension 3.53[0.97–13] 0.06 10.1[1.1–92] 0.04
+Smoke, current 1.80[0.37–8.8] 0.47 8.40[1.3–55] 0.03
+Family History of CVD 2.70[0.55–13] 0.22 3.12[0.46–21] 0.24
+BMI 0.790[0.64–0.97] 0.026 0.893[0.70–1.1] 0.35
Adjusting for circulating inflammatory markers
Model III Presence of MCI p-value Presence of MCI50 p-value
Presence of SLE and RA 4.87[0.97–24] 0.055 6.78[1.2–40] 0.03
+Female 0.659[0.16–2.7] 0.56 1.02[0.22–4.7] 0.98
+Age 0.999[0.93–1.1] 0.98 1.01[0.94–1.1] 0.77
+CRP 1.12[1.0–1.2] 0.03 1.01[0.91–1.1] 0.86
+C3 1.13[0.10–13] 0.92 13.7[0.93–203] 0.06
+TCC 0.941[0.16–5.7] 0.95 1.09[0.15–7.9] 0.93
+Pentraxin 3 0.271[0.10–0.71] 0.008 0.563[0.22–1.4] 0.22
Body mass index (BMI), C-reactive protein (CRP), Low Density Lipoprotein (LDL), Pentraxin3 (PTX3), Terminal Complement Complex (TCC).
*History of Thrombosis: myocardial infarction (MI), stroke, acute coronary syndrome (ACS), deep vein thrombosis (DVT), or pulmonary embolism
https://doi.org/10.1371/journal.pone.0174577.t003
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Fig 1. Complement activation product, C3d, presence within the vascular media and adventitia sections for IRDCAD
(SLE and RA) and non-IRDCAD only patients. A-C) C3d deposition in the aorta media of all biopsies; D-F) Isotype control
—aorta media; G-I) C3d deposition in the aorta adventitia: diffusely in SLE (G), focally in RA (H), and none in non-IRD (I);
J-L) Isotype control—aorta adventitia. All images 10x.
https://doi.org/10.1371/journal.pone.0174577.g001
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particularly crucial for both systemic and vascular inflammation in SLE and RA, in order to
reduce CVD morbidity.
There are some limitations in this study including the relatively small SLE and RA popula-
tion and the cross-sectional design. The rarity of this type of tissue is evidenced by the FHBS
obtaining only 3 SLE CABG aortic medial and adventitial biopsies during a five-year period.
The surgical biopsies have a great advantage compared to autopsy specimens as they are not
deteriorated by post mortem processes. Additionally, we have not been able to examine other
biopsied tissue. Due to ethical reasons and feasibility, we were not able to obtain aortic speci-
mens from either IRD population without CAD or healthy individuals for comparison.
Conclusions
In conclusion, among CABG patients, IRD patients had higher p-TCC and more complement
activation in the vascular adventitia when compared to non-IRD patients. The pronounced
adventitial complement activation in SLE patients might be due to the unique role of comple-
ment in SLE. Exaggerated systemic and vascular complement activation may accelerate CVD
development, but also may serve as CVD biomarkers and represent new targets for CVD
therapies.
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